Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing?

Authors

Institutions

Publication Details

Journal
Clinical Trials
Published
2025-04-01
DOI
https://doi.org/10.1177/17407745251324865
Citations
5
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
6.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing?

John G.F. Cleland, Danyaal Anzar
5 citations
Clinical Trials
Antiplatelet Therapy and Cardiovascular Diseases
6.94
article

Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing?

John G.F. Cleland, Danyaal Anzar
article en
5 citations

Abstract

No abstract available for this paper.
Clinical TrialsVol. 22(4)
British Heart Foundation (GB), University of Glasgow (GB)
Openalex Percentile: Top 3%
Antiplatelet Therapy and Cardiovascular Diseases
6.94
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Commentary on Wittes et al: Aspirin for primary prevention of CV events – Rationally robust? Statistically significant? Clinically convincing? — John G.F. Cleland, Danyaal Anzar · Clinical Trials (2025) | TGRS Research Map | TGRS